These inhibitors were selected based on their previously reported efficacy in hematological malignancies to explore their potential synergistic effects blocking the Hedgehog and PI3K/Akt/mTOR pathways simultaneously [26,27,28,29,30,31,32]. This evidence concerns the gene MTOR and hematologic disorder.